BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 22479645)

  • 1. Stromal interferon-γ signaling and cross-presentation are required to eliminate antigen-loss variants of B cell lymphomas in mice.
    Gerbitz A; Sukumar M; Helm F; Wilke A; Friese C; Fahrenwaldt C; Lehmann FM; Loddenkemper C; Kammertoens T; Mautner J; Schmitt CA; Blankenstein T; Bornkamm GW
    PLoS One; 2012; 7(3):e34552. PubMed ID: 22479645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Critical role of the NKG2D receptor for NK cell-mediated control and immune escape of B-cell lymphoma.
    Belting L; Hömberg N; Przewoznik M; Brenner C; Riedel T; Flatley A; Polić B; Busch DH; Röcken M; Mocikat R
    Eur J Immunol; 2015 Sep; 45(9):2593-601. PubMed ID: 26151313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD19 is a major B cell receptor-independent activator of MYC-driven B-lymphomagenesis.
    Chung EY; Psathas JN; Yu D; Li Y; Weiss MJ; Thomas-Tikhonenko A
    J Clin Invest; 2012 Jun; 122(6):2257-66. PubMed ID: 22546857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pre-germinal center origin for mature mouse B cell lymphomas: a major discrepancy with human mature lymphomas.
    Saintamand A; Garot A; Saad F; Moulinas R; Denizot Y
    Cell Cycle; 2015; 14(22):3656-8. PubMed ID: 26654599
    [No Abstract]   [Full Text] [Related]  

  • 5. Induction of antigen-specific effector-phase tolerance following vaccination against a previously ignored B-cell lymphoma.
    Prato S; Mintern JD; Lahoud MH; Huang DC; Villadangos JA
    Immunol Cell Biol; 2011 Jul; 89(5):595-603. PubMed ID: 21079642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Transcription Factor ASCIZ and Its Target DYNLL1 Are Essential for the Development and Expansion of MYC-Driven B Cell Lymphoma.
    Wong DM; Li L; Jurado S; King A; Bamford R; Wall M; Walia MK; Kelly GL; Walkley CR; Tarlinton DM; Strasser A; Heierhorst J
    Cell Rep; 2016 Feb; 14(6):1488-1499. PubMed ID: 26832406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A non-transgenic mouse model for B-cell lymphoma: in vivo infection of p53-null bone marrow progenitors by a Myc retrovirus is sufficient for tumorigenesis.
    Yu D; Thomas-Tikhonenko A
    Oncogene; 2002 Mar; 21(12):1922-7. PubMed ID: 11896625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic anti-tumor response induced with epitope-pulsed fibroblasts genetically engineered for B7.1 expression and IFN-gamma secretion.
    Kim TS; Chung SW; Kim SH; Kang SN; Kang BY
    Int J Cancer; 2000 Aug; 87(3):427-33. PubMed ID: 10897050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Requirements for control of B-cell lymphoma by NK cells.
    Brenner CD; King S; Przewoznik M; Wolters I; Adam C; Bornkamm GW; Busch DH; Röcken M; Mocikat R
    Eur J Immunol; 2010 Feb; 40(2):494-504. PubMed ID: 19950185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity.
    Schmidt-Wolf IG; Negrin RS; Kiem HP; Blume KG; Weissman IL
    J Exp Med; 1991 Jul; 174(1):139-49. PubMed ID: 1711560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gamma interferon produced by antigen-specific CD4+ T cells regulates the mucosal immune responses to Citrobacter rodentium infection.
    Shiomi H; Masuda A; Nishiumi S; Nishida M; Takagawa T; Shiomi Y; Kutsumi H; Blumberg RS; Azuma T; Yoshida M
    Infect Immun; 2010 Jun; 78(6):2653-66. PubMed ID: 20351140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genomic characterisation of Eμ-Myc mouse lymphomas identifies Bcor as a Myc co-operative tumour-suppressor gene.
    Lefebure M; Tothill RW; Kruse E; Hawkins ED; Shortt J; Matthews GM; Gregory GP; Martin BP; Kelly MJ; Todorovski I; Doyle MA; Lupat R; Li J; Schroeder J; Wall M; Craig S; Poortinga G; Cameron D; Bywater M; Kats L; Gearhart MD; Bardwell VJ; Dickins RA; Hannan RD; Papenfuss AT; Johnstone RW
    Nat Commun; 2017 Mar; 8():14581. PubMed ID: 28262675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interferon-gamma mediates antigen trafficking to MHC class II-positive late endosomes of enterocytes.
    Büning J; Schmitz M; Repenning B; Ludwig D; Schmidt MA; Strobel S; Zimmer KP
    Eur J Immunol; 2005 Mar; 35(3):831-42. PubMed ID: 15688349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Eµ-hnRNP K Murine Model of Lymphoma: Novel Insights into the Role of hnRNP K in B-Cell Malignancies.
    Malaney P; Velasco-Estevez M; Aguilar-Garrido P; Aitken MJL; Chan LE; Zhang X; Post SM; Gallardo M
    Front Immunol; 2021; 12():634584. PubMed ID: 33912162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MYC-driven malignant transformation of mature murine B cells requires inhibition of both intrinsic apoptosis and p53 activity.
    Högstrand K; Grandien A
    Eur J Immunol; 2019 Mar; 49(3):375-385. PubMed ID: 30281155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recruitment of natural killer cells in advanced stages of endogenously arising B-cell lymphoma: implications for therapeutic cell transfer.
    Przewoznik M; Hömberg N; Naujoks M; Pötzl J; Münchmeier N; Brenner CD; Anz D; Bourquin C; Nelson PJ; Röcken M; Mocikat R
    J Immunother; 2012 Apr; 35(3):217-22. PubMed ID: 22421939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IFN-γ treatment protocol for MHC-I
    Stifter K; Krieger J; Ruths L; Gout J; Mulaw M; Lechel A; Kleger A; Seufferlein T; Wagner M; Schirmbeck R
    J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32868392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suppression of antigen-specific CD4+ T cell activation by SRA/CD204 through reducing the immunostimulatory capability of antigen-presenting cell.
    Yi H; Zuo D; Yu X; Hu F; Manjili MH; Chen Z; Subjeck JR; Wang XY
    J Mol Med (Berl); 2012 Apr; 90(4):413-26. PubMed ID: 22083206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IFN-gamma- and TNF-dependent bystander eradication of antigen-loss variants in established mouse cancers.
    Zhang B; Karrison T; Rowley DA; Schreiber H
    J Clin Invest; 2008 Apr; 118(4):1398-404. PubMed ID: 18317595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unexpected suppression of tumorigenesis by c-MYC via TFAP4-dependent restriction of stemness in B lymphocytes.
    Tonc E; Takeuchi Y; Chou C; Xia Y; Holmgren M; Fujii C; Raju S; Chang GS; Iwamoto M; Egawa T
    Blood; 2021 Dec; 138(24):2526-2538. PubMed ID: 34283887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.